title: A seroprevalence study of poliovirus antibody in the population of northern Greece.
abstract: This study assessed immunity to poliomyelitis in a representative sample of 1064 persons living in northern Greece. Antibody prevalences in the individuals tested were 91.1% (95% confidence interval (CI): 89.4-92.8), 92.1% (95% CI: 90.5-93.7) and 83.1% (95% CI: 80.8-85.4) for poliovirus types 1, 2 and 3, respectively. For poliovirus type 3, a gap in immunity was found in individuals aged 10-29 years. Re-vaccination of adolescents living in northern Greece is suggested to ensure herd immunity and to minimise the risk of importation of wild poliovirus from endemic countries.
authors.affiliation: 'A' Department of Microbiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. filanthi@med.auth.gr
authors.forename: F
authors.initials: F
authors.lastname: Frantzidou
authors.forename: E
authors.initials: E
authors.lastname: Diza
authors.forename: D
authors.initials: D
authors.lastname: Halkia
authors.forename: A
authors.initials: A
authors.lastname: Antoniadis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006115:Greece / Q000453:epidemiology; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D011051:Poliomyelitis / Q000453:epidemiology* / Q000276:immunology / Q000821:virology; D017955:Poliovirus / Q000276:immunology*; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000276:immunology; D015995:Prevalence; D016036:Seroepidemiologic Studies; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral